-
SB 431542: ALK5 Inhibitor Workflow
2026-08-28
Use SB 431542 to separate TGF-β receptor activity from downstream differentiation, migration, proliferation, and immune phenotypes. This practical workflow adapts a serum-free hiPSC-to-corneal endothelial model while adding dose controls, orthogonal readouts, and troubleshooting guidance.
-
PBS Liposomes for Macrophage Depletion Controls
2026-08-28
PBS Liposomes reproduce macrophage uptake without clodronate-driven apoptosis, making them a critical negative control for interpreting depletion experiments. Use them in matched in vivo designs, phagocytosis assays, and tissue analyses to separate liposome handling from macrophage loss.
-
Chloroquine Diphosphate: Flux to Function
2026-08-27
Chloroquine Diphosphate is more than an autophagy reagent: it is a strategic perturbation tool for separating lysosomal effects from apoptosis, ferroptosis, and treatment resistance. This guide explains how to use it rigorously in cancer research and combination-treatment assays.
-
Staurosporine in Redox-Stress Assay Design
2026-08-27
Staurosporine is a broad-spectrum serine/threonine protein kinase inhibitor that can serve as a powerful perturbation control in stress-response assays. This guide connects kinase inhibition with the GCLC–glutathione biology of age-related cataract research while defining practical limits for interpretation.
-
Radiotherapy, PD-1/TIGIT Blockade, and CD8+ Memory
2026-08-26
The reference study shows that radiotherapy combined with PD-1 and TIGIT blockade can extend local tumor control into abscopal protection and durable immune memory in several syngeneic mouse models. Its mechanistic contribution is the integration of CD8+ T-cell reinvigoration with M1 macrophage activation, cytokine signaling, and central-memory formation.
-
Mavorixafor: Translational CXCR4 Strategy
2026-08-26
A mechanism-to-clinic perspective on mavorixafor hydrochloride, showing how CXCR4 biology, assay design, clinical evidence, and disease-focused strategy can be connected for translational research.
-
AM 281: Mapping CB1–GLT-1 Cognitive Signaling
2026-08-25
AM 281 is a selective CB1 cannabinoid receptor antagonist for dissecting how endocannabinoid signaling, astrocytic GLT-1, and glutamate excitotoxicity shape cognitive dysfunction. This article translates recent traumatic brain injury findings into a cell-aware framework for memory impairment research and assay interpretation.
-
Caspase-8 Fluorometric Assay Kit Workflow
2026-08-25
Translate IETD-dependent caspase activity into a rapid fluorescence readout for apoptosis, combination-therapy, and programmed cell death research. This workflow also shows how to separate direct Caspase-8 activity measurement from downstream apoptosis or pyroptosis phenotypes.
-
IEM 1460: AMPA Receptor Blocker Workflow
2026-08-24
IEM 1460 enables controlled AMPA receptor inhibition assays for separating fast glutamatergic signaling from downstream excitotoxic injury. This practical guide covers stock preparation, neuronal workflows, electrophysiology, data interpretation, and troubleshooting while distinguishing product-specific evidence from findings reported for the related dual antagonist IEM-1925.
-
1-Phenyl-2-Pentanol and Hepatic Fibrosis
2026-08-24
The reference study identifies 1-phenyl-2-pentanol from Moringa oleifera Lam. leaves as an inhibitor of profibrotic activation in TGF-β1-stimulated human LX-2 hepatic stellate cells. By combining fibrosis-marker analysis, proteomics, and molecular docking, it links the compound’s activity to modulation of TGF-β1 and Wnt/β-catenin signaling while defining important limits for translation beyond cell culture.
-
U-73122: Phospholipase C Inhibitor Workflows
2026-08-23
U-73122 is a practical phospholipase C inhibitor for connecting PLC activity with calcium flux, chemotaxis, and cancer-cell motility. This workflow-focused guide shows how to prepare, dose, and validate the compound while separating pathway-specific effects from cytotoxicity or assay artifacts.
-
High-Throughput Imaging of Fractional Drug Killing
2026-08-22
Inde, Rodencal, and Dixon present a microscopy-based protocol for measuring drug-induced fractional killing as a time-resolved population phenotype rather than relying on a single endpoint. The workflow combines nuclear fluorescent labeling, live/dead imaging, and automated analysis to compare many treatment conditions and reveal variability in MEK1/2 inhibitor responses.
-
Phillygenin and Signaling Pathways in Diabetic Nephropathy
2026-08-21
The reference study identifies phillygenin as a candidate intervention for diabetic nephropathy and connects its protective effects to coordinated suppression of TLR4/MyD88/NF-κB inflammation and restoration of PI3K/AKT/GSK3β signaling. By combining high-glucose podocyte experiments, RNA sequencing, biochemical assays, and db/db mouse studies, the work links reduced inflammatory injury and apoptosis with improved renal function.
-
EMD638683: Practical SGK1 Inhibitor Workflows
2026-08-20
EMD638683 supports mechanism-focused studies that connect SGK1 activity with NDRG1 phosphorylation, actin remodeling, endothelial stiffness, and stress responses. This workflow-oriented guide helps researchers compare pharmacological and genetic evidence while optimizing solubility, dosing, controls, and phenotypic readouts.
-
M344: From Chromatin Biology to Translational Strategy
2026-08-20
M344 is a cell-permeable histone deacetylase inhibitor that connects chromatin remodeling with cancer-cell differentiation, proliferation control, radiation response, and HIV-1 latency research. This thought-leadership guide translates its mechanistic profile into practical experimental design while defining the evidence boundaries between in vitro discovery and clinical translation.